The Institute of Cancer Research shared a post on LinkedIn:

“Calling companies and potential partners working in oncology!

Are you attending BioTrinity 2024 in the City of London this week?

A team from our Business and Innovation Office will be there to speak to possible partners, collaborators and funders about opportunities to work with us across a broad portfolio of our cancer research.

As one of the top-rated UK academic organisations in industry collaboration, we currently work with around 100 commercial partners to develop our discoveries into new cancer treatments. Highlights in the past year include the Food and Drug Administration (FDA) approval of breast cancer drug capivasertib (now branded Truqap), which was discovered by AstraZeneca following a long-running collaborative research programme also including Astex Pharmaceuticals.

Come and meet our team at BioTrinity (Ceri Mathews, Joo-Hee Sir, Jennifer Hodgson and Jonathan Beech) to discuss partnering with us, or joining our network of VCs and potential investors.

If you are already registered to attend BioTrinity 2024, you can set up a meeting via the link.”

Source: The Institute of Cancer Research/LinkedIn